

# High Levels of Circulating Insulin-Like Growth Factor-I Prospective Study in a Population-Based Nonscreened Cohort

Journal of Clinical Oncology

22, 3104-3112

DOI: 10.1200/jco.2004.10.105

Citation Report

#	ARTICLE	IF	CITATIONS
1	A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. <i>Oncogene</i> , 2005, 24, 4736-4740.	5.9	58
2	Insulin-like Growth Factor 1, Chromogranin A and Prostate Specific Antigen Serum Levels in Prostate Cancer Patients and Controls. <i>European Urology</i> , 2005, 48, 34-39.	1.9	20
3	Insulin-like growth factor I treatment for cerebellar ataxia: Addressing a common pathway in the pathological cascade?. <i>Brain Research Reviews</i> , 2005, 50, 134-141.	9.0	39
4	Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. <i>Cancer Causes and Control</i> , 2005, 16, 255-262.	1.8	65
5	Prostate Cancer Risk Among Men with Diabetes Mellitus (Spain). <i>Cancer Causes and Control</i> , 2005, 16, 1055-1058.	1.8	48
6	Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men. <i>Prostate Cancer and Prostatic Diseases</i> , 2005, 8, 84-90.	3.9	10
7	Effect of the Synthetic Retinoid Fenretinide on Circulating Free Prostate-Specific Antigen, Insulin-Like Growth Factor-I, and Insulin-Like Growth Factor Binding Protein-3 Levels in Men with Superficial Bladder Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 2083-2088.	7.0	6
8	A Prospective Study of the Insulin-Like Growth Factor Axis in Relation with Prostate Cancer in the SU.VI.MAX Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2269-2272.	2.5	18
9	Prognostic value of serum markers for prostate cancer. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005, 39, 64-81.	1.4	63
10	PROSTATE SPECIFIC ANTIGEN LEVELS IN YOUNG ADULTHOOD PREDICT PROSTATE CANCER RISK: RESULTS FROM A COHORT OF BLACK AND WHITE AMERICANS. <i>Journal of Urology</i> , 2005, 174, 872-876.	0.4	75
11	Biochemical and Structural Characterization of a Novel Class of Inhibitors of the Type 1 Insulin-like Growth Factor and Insulin Receptor Kinases. <i>Biochemistry</i> , 2005, 44, 9430-9440.	2.5	31
12	Novel insights into the implication of the IGF-1 network in prostate cancer. <i>Trends in Molecular Medicine</i> , 2005, 11, 52-55.	6.7	62
13	Association between body mass index and prostate cancer detection rates in Japanese urologic patients. <i>Urology</i> , 2005, 66, 130-134.	1.0	14
14	Racial and anthropometric differences in plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein-3. <i>Urology</i> , 2005, 66, 587-592.	1.0	21
15	What Can Geography Tell Us About Prostate Cancer?. <i>American Journal of Preventive Medicine</i> , 2006, 30, S7-S15.	3.0	40
16	Castration rapidly decreases local insulin-like growth factor-1 levels and inhibits its effects in the ventral prostate in mice. <i>Prostate</i> , 2006, 66, 1687-1697.	2.3	19
17	Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. <i>British Journal of Pharmacology</i> , 2006, 147, S144-S152.	5.4	64
18	Insulin-Like Growth Factor (IGF) family and prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 58, 124-145.	4.4	135

#	ARTICLE	IF	CITATIONS
19	Apoptosis evasion: The role of survival pathways in prostate cancer progression and therapeutic resistance. Journal of Cellular Biochemistry, 2006, 97, 18-32.	2.6	110
20	Recreational physical activity and risk of prostate cancer: A prospective population-based study in Norway (the HUNT study). International Journal of Cancer, 2006, 119, 2943-2947.	5.1	111
21	Common Genetic Variation in IGF1 and Prostate Cancer Risk in the Multiethnic Cohort. Journal of the National Cancer Institute, 2006, 98, 123-134.	6.3	107
22	Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1137-1141.	2.5	59
23	Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies. British Journal of Cancer, 2006, 95, 112-117.	6.4	64
24	The IGF Axis in Prostate Cancer. Current Pharmaceutical Design, 2007, 13, 719-727.	1.9	37
25	Implications for Prostate Cancer of Insulin-Like Growth Factor-I (IGF-I) Genetic Variation and Circulating IGF-I Levels. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4820-4826.	3.6	37
26	Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor. Clinical Cancer Research, 2007, 13, 3611-3616.	7.0	185
27	Haplotype-Based Analysis of Common Variation in the Growth Hormone Receptor Gene and Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 169-173.	2.5	17
28	A mechanism to explain how regular exercise might reduce the risk for clinical prostate cancer. European Journal of Cancer Prevention, 2007, 16, 415-421.	1.3	52
29	Overweight/obesity and cancer genesis: More than a biological link. Biomedicine and Pharmacotherapy, 2007, 61, 665-678.	5.6	83
30	Lignans and Human Health. Critical Reviews in Clinical Laboratory Sciences, 2007, 44, 483-525.	6.1	425
31	Combined Inhibitory Effects of Green Tea Polyphenols and Selective Cyclooxygenase-2 Inhibitors on the Growth of Human Prostate Cancer Cells Both In vitro and In vivo. Clinical Cancer Research, 2007, 13, 1611-1619.	7.0	197
32	Molecular epidemiology of prostate cancer: hormone-related genetic loci. Frontiers in Bioscience - Landmark, 2007, 12, 3436.	3.0	40
33	Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer. International Journal of Cancer, 2007, 120, 539-542.	5.1	24
34	Insulin resistance is inversely related to prostate cancer: A prospective study in Northern Sweden. International Journal of Cancer, 2007, 120, 2678-2686.	5.1	84
35	SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer. International Journal of Cancer, 2007, 121, 615-620.	5.1	31
36	IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. International Journal of Cancer, 2007, 121, 2267-2273.	5.1	53

#	ARTICLE	IF	CITATIONS
37	Androgens and prostate cancer risk: A prospective study. Prostate, 2007, 67, 1230-1237.	2.3	29
38	Hypoxia-inducible factor-1 $\pm$ (HIF-1 $\pm$ ) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. Prostate, 2007, 67, 1354-1361.	2.3	49
39	The impact of obesity on prostate cancer. World Journal of Urology, 2007, 25, 491-497.	2.2	17
40	Metabolic syndrome in sub-Saharan Africa: â€œsmaller twinâ€ of a regionâ€™s prostatic diseases?. International Urology and Nephrology, 2008, 40, 909-920.	1.4	17
41	Lifetime total physical activity and prostate cancer risk: a population-based caseâ€“control study in Sweden. European Journal of Epidemiology, 2008, 23, 739-746.	5.7	31
42	Differential localization of MT1â€™MMP in human prostate cancer tissue: Role of IGFâ€™R in MT1â€™MMP expression. Prostate, 2008, 68, 463-476.	2.3	19
43	Practical Examples: Hormones. , 0, , 309-321.		0
44	Nutrition, metabolic factors and cancer risk. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 551-571.	4.7	64
45	Endocannabinoids in endocrine and related tumours. Endocrine-Related Cancer, 2008, 15, 391-408.	3.1	59
46	Glycemic Status and Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 628-635.	2.5	22
47	Targeted Deletion of Hepatic Igf1 in TRAMP Mice Leads to Dramatic Alterations in the Circulating Insulin-Like Growth Factor Axis but Does Not Reduce Tumor Progression. Cancer Research, 2008, 68, 3342-3349.	0.9	52
48	Role of Hormonal and Other Factors in Human Prostate Cancer. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2008, 11, 242-259.	6.5	51
49	Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies. Annals of Internal Medicine, 2008, 149, 461.	3.9	263
50	The Epidemiologic Relationship between Diabetes and Cancer. Frontiers in Diabetes, 2008, , 84-96.	0.4	2
52	The insulin-like growth factor system and its receptors: A potential novel anticancer target. Biologics: Targets and Therapy, 2008, 2, 855.	3.2	6
53	One-Carbon Metabolism and Prostate Cancer Risk: Prospective Investigation of Seven Circulating B Vitamins and Metabolites. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1538-1543.	2.5	70
54	Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ: British Medical Journal, 2009, 339, b3537-b3537.	2.3	102
55	NKX3.1 Activates Expression of Insulin-like Growth Factor Binding Protein-3 to Mediate Insulin-like Growth Factor-I Signaling and Cell Proliferation. Cancer Research, 2009, 69, 2615-2622.	0.9	19

#	ARTICLE	IF	CITATIONS
57	Cancer Incidence in Israeli Jewish Survivors of World War II. Journal of the National Cancer Institute, 2009, 101, 1489-1500.	6.3	96
58	Genetic Variation in the SST Gene and its Receptors in Relation to Circulating Levels of Insulin-Like Growth Factor-I, IGFBP3, and Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1644-1650.	2.5	10
59	Circulating insulin-like growth factor peptides and prostate cancer risk: A systematic review and meta-analysis. International Journal of Cancer, 2009, 124, 2416-2429.	5.1	222
60	Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival. Prostate, 2009, 69, 1281-1291.	2.3	24
61	Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. European Journal of Human Genetics, 2009, 17, 1668-1675.	2.8	94
62	Implications of insulin-like growth factor for prostate cancer therapies. International Journal of Urology, 2009, 16, 161-167.	1.0	55
63	Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness?. BJU International, 2009, 104, 1200-1203.	2.5	5
64	No association between insulin-like growth factor I and prostate cancer risk. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2009, 3, 132-138.	3.6	0
65	Relationship of Insulin-Like Growth Factors System Gene Polymorphisms with the Susceptibility and Pathological Development of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2010, 17, 1808-1815.	1.5	62
66	Relationship between serum levels of insulin-like growth factors and subsequent risk of cancer mortality: Findings from a nested case-control study within the Japan Collaborative Cohort Study. Cancer Epidemiology, 2010, 34, 279-284.	1.9	7
67	Insulin-Like Growth Factor I Suppresses Bone Morphogenetic Protein Signaling in Prostate Cancer Cells by Activating mTOR Signaling. Cancer Research, 2010, 70, 9106-9117.	0.9	25
68	Plasma Levels of Acid-Labile Subunit, Free Insulin-Like Growth Factor-I, and Prostate Cancer Risk: A Prospective Study. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 484-491.	2.5	16
69	Circulating steroid hormones in prostate carcinogenesis. Part 1 - Androgens. Hormone Molecular Biology and Clinical Investigation, 2010, 3, 341-56.	0.7	0
70	A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Human Molecular Genetics, 2010, 19, 3089-3101.	2.9	47
71	2011 and beyond. Mental Health and Substance Use: Dual Diagnosis, 2011, 4, 1-2.	0.5	1
72	Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: A review. Molecular and Cellular Endocrinology, 2011, 344, 1-24.	3.2	66
74	Nutrigenetics and Prostate Cancer: 2011 and Beyond. Journal of Nutrigenetics and Nutrigenomics, 2011, 4, 121-136.	1.3	10
75	Human prostate cancer xenografts in mice exhibit reduced growth and androgen-independent progression. Prostate, 2011, 71, 525-537.	2.3	19

#	ARTICLE	IF	CITATIONS
76	Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004. <i>International Journal of Cancer</i> , 2011, 128, 660-667.	5.1	31
77	Dietary intakes of carbohydrates in relation to prostate cancer risk: a prospective study in the Malmö Diet and Cancer cohort. <i>American Journal of Clinical Nutrition</i> , 2012, 96, 1409-1418.	4.7	80
78	The association of diabetes and positive prostate biopsy in a US veteran population. <i>Prostate Cancer and Prostatic Diseases</i> , 2012, 15, 70-74.	3.9	20
79	Prostate Carcinogenesis with Diabetes and Androgen-Deprivation-Therapy-Related Diabetes: An Update. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-8.	3.8	10
81	Insulin-like Growth Factors and Cancer. , 2012, , .		16
82	Association between Circulating Levels of IGF-1 and IGFBP-3 and Lung Cancer Risk: A Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e49884.	2.5	45
83	Periacinar Retraction Cleaving in Nonneoplastic and Neoplastic Prostatic Glands: Artifact or Molecular Involvement. <i>Pathology and Oncology Research</i> , 2012, 18, 285-292.	1.9	11
84	Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: Longitudinal study. <i>International Journal of Cancer</i> , 2012, 130, 129-137.	5.1	31
85	Time-regulated drug delivery system based on coaxially incorporated platelet $\alpha$ -granules for biomedical use. <i>Nanomedicine</i> , 2013, 8, 1137-1154.	3.3	25
86	Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal Prostate Cancer: A Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1984-1993.	2.5	41
87	Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 491-498.	2.5	15
88	Metabolic Syndrome as a Peculiar Target for Management of Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 211-220.	1.9	17
89	Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer. <i>Genes and Cancer</i> , 2013, 4, 535-545.	1.9	3
90	Evidence for the Possible Biological Significance of the igf-1 Gene Alternative Splicing in Prostate Cancer. <i>Frontiers in Endocrinology</i> , 2013, 4, 31.	3.5	28
91	Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling. <i>Cancer Prevention Research</i> , 2013, 6, 801-810.	1.5	74
92	Urinary <i>IGF</i> , IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer. <i>Biomarkers in Medicine</i> , 2013, 7, 831-841.	1.4	12
93	Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: A randomized study. <i>Canadian Urological Association Journal</i> , 2013, 7, 692.	0.6	37
94	Effects of Calorie Restriction and IGF-1 Receptor Blockade on the Progression of 22Rv1 Prostate Cancer Xenografts. <i>International Journal of Molecular Sciences</i> , 2013, 14, 13782-13795.	4.1	26

#	ARTICLE	IF	CITATIONS
95	Association of Polymorphisms and Haplotypes in the Insulin-Like Growth Factor 1 Receptor (IGF1R) Gene with the Risk of Breast Cancer in Korean Women. PLoS ONE, 2014, 9, e84532.	2.5	27
96	Prostate cancer: the need for biomarkers and new therapeutic targets. Journal of Zhejiang University: Science B, 2014, 15, 16-42.	2.8	26
97	Coffee consumption and prostate cancer risk: an updated meta-analysis. Cancer Causes and Control, 2014, 25, 591-604.	1.8	40
98	Insulin-like growth factor receptor-1 (IGF-1R) as a target for prostate cancer therapy. Cancer and Metastasis Reviews, 2014, 33, 607-617.	5.9	38
99	SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. Carcinogenesis, 2014, 35, 24-33.	2.8	42
100	Persistent androgen receptor addiction in castration-resistant prostate cancer. Journal of Hematology and Oncology, 2015, 8, 128.	17.0	59
101	Novel Aspects Concerning the Functional Cross-Talk between the Insulin/IGF-I System and Estrogen Signaling in Cancer Cells. Frontiers in Endocrinology, 2015, 6, 30.	3.5	42
102	A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 701-711.	7.0	86
103	Evidence of estrone-sulfate uptake modification in young and middle-aged rat prostate. Journal of Steroid Biochemistry and Molecular Biology, 2015, 152, 89-100.	2.5	21
104	Antioxidant and Anticoagulant Status Were Improved by Personalized Dietary Intervention Based on Biochemical and Clinical Parameters in Cancer Patients. Nutrition and Cancer, 2015, 67, 1083-1092.	2.0	20
105	Lactose intolerance and risk of lung, breast and ovarian cancers: aetiological clues from a population-based study in Sweden. British Journal of Cancer, 2015, 112, 149-152.	6.4	48
106	A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients. Prostate Cancer and Prostatic Diseases, 2016, 19, 323-332.	3.9	20
108	Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? A systematic review and meta-analysis. Cancer Causes and Control, 2017, 28, 497-528.	1.8	65
109	Dairy Intake During the Adolescence Period and Risk of Prostate and Breast Cancer. , 2017, , 429-434.		0
110	Glucose impairments and insulin resistance in prostate cancer: the role of obesity, nutrition and exercise. Obesity Reviews, 2018, 19, 1008-1016.	6.5	44
111	Carbohydrate Nutrition and the Risk of Cancer. Current Nutrition Reports, 2019, 8, 230-239.	4.3	33
112	Identification of metabolites associated with prostate cancer risk: a nested case-control study with long follow-up in the Northern Sweden Health and Disease Study. BMC Medicine, 2020, 18, 187.	5.5	21
113	Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports. Biomolecules, 2021, 11, 217.	4.0	34

#	ARTICLE	IF	CITATIONS
114	The Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 735374.	3.7	16
115	Genetic Polymorphisms in IGF-I and IGFBP-3 Are Associated with Prostate Cancer in the Chinese Population. <i>PLoS ONE</i> , 2014, 9, e85609.	2.5	18
116	Genetic and Dietary Determinants of Insulin-Like Growth Factor (IGF)-1 and IGF Binding Protein (BP)-3 Levels among Chinese Women. <i>PLoS ONE</i> , 2014, 9, e108934.	2.5	13
117	Prostate cancer epidemiology. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 1388.	3.0	331
118	Epidemiology of Breast, Prostate, and Colon Cancers. <i>Nutrition and Disease Prevention</i> , 2005, , .	0.1	0
119	Somatomedin C (IGF-1), Dehydroepiandrosterone Sulphate (DHEA-S) and Hcy Metabolism in Postmenopausal African Women. <i>Journal of Medical Sciences (Faisalabad, Pakistan)</i> , 2006, 6, 734-742.	0.0	1
120	The Epidemiology of Prostate Cancer. , 2010, , 3-49.		0
121	The Role of the IGF Axis in Human Malignancy: Evidence from Epidemiological Studies and Tissue Analysis. <i>Energy Balance and Cancer</i> , 2011, , 213-242.	0.2	0
122	Epidemiology of IGF-1 and Cancer. , 2012, , 1-24.		0
124	10 Prostate Cancer. , 2017, , 231-250.		0
126	Hormonal patterns in men with prediabetes and diabetes in NHANES III: possible links with prostate cancer. <i>Cancer Causes and Control</i> , 2022, 33, 429-440.	1.8	3
128	Identification of prediagnostic metabolites associated with prostate cancer risk by untargeted mass spectrometryâ€based metabolomics: A caseâ€control study nested in the Northern Sweden Health and Disease Study. <i>International Journal of Cancer</i> , 2022, 151, 2115-2127.	5.1	3
129	Obesity and prostate cancer. , 2023, , 115-128.		0
131	High adherence to Western dietary pattern and prostate cancer risk: findings from the <scp>EPICâ€Spain</scp> cohort. <i>BJU International</i> , 2023, 132, 272-282.	2.5	1
132	Role of tumor microenvironment in prostate cancer therapy resistance. , 2024, , 27-56.		0